LOC105376161: A Potential Drug Target or Biomarker (G105376161)
LOC105376161: A Potential Drug Target or Biomarker
LOC105376161 (LOC105376161 variant X2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a member of the protein kinase CKL (Ca2+-dependent protein kinase like) family and is involved in a variety of cellular processes, including cell signaling, metabolism, and inflammation.
LOC105376161 variant X2 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its function in these diseases has been studied extensively, and its potential as a drug target has been evaluated using various techniques, including cell-based assays, animal models, and human clinical trials.
One of the main reasons for the interest in LOC105376161 is its potential as a drug target for cancer. Cancer is a leading cause of death worldwide, and there is a high demand for new treatments that can effectively inhibit the growth and spread of cancer cells. LOC105376161 has been shown to be involved in the regulation of cell proliferation and has been found to be expressed in various types of cancer cells.
In addition to its potential as a cancer drug target, LOC105376161 has also been studied for its potential as a neurodegenerative disease biomarker. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and are often treated with drugs that aim to slow down or halt the progression of these diseases.
LOC105376161 has been shown to be involved in the regulation of neurotransmitter signaling, which is a critical aspect of brain function. Its expression has been found to be associated with the release of neurotransmitters, such as dopamine and serotonin, which are involved in mood, emotion, and cognitive processes. Additionally, LOC105376161 has been shown to play a role in the regulation of neurotransmitter receptors, which are the proteins that receive neurotransmitters and transmit signals to the brain.
Another potential application of LOC105376161 is as a biomarker for metabolic disorders. Metabolic disorders, such as type 2 diabetes, are characterized by imbalances in the levels of glucose in the blood. LOC105376161 has been shown to be involved in the regulation of glucose metabolism, and its expression has been found to be associated with the sensitivity of cells to insulin.
In addition to its potential as a drug target or biomarker, LOC105376161 has also been studied for its effects on cellular processes such as cell signaling, metabolism, and inflammation. Its expression has been found to be involved in the regulation of various cellular processes, including cell adhesion, migration, and apoptosis (programmed cell death).
Overall, LOC105376161 (LOC105376161 variant X2) is a protein that has significant potential as a drug target or biomarker for various diseases. Its function in cell signaling, metabolism, and inflammation makes it an attractive target for the development of new treatments for cancer, neurodegenerative diseases, and metabolic disorders. Further research is needed to fully understand its potential and to develop safe and effective drugs that can target LOC105376161.
Protein Name: Uncharacterized LOC105376161
The "LOC105376161 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC105376161 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC105376169 | LOC105376171 | LOC105376177 | LOC105376187 | LOC105376193 | LOC105376196 | LOC105376205 | LOC105376206 | LOC105376208 | LOC105376211 | LOC105376214 | LOC105376219 | LOC105376223 | LOC105376225 | LOC105376234 | LOC105376244 | LOC105376247 | LOC105376250 | LOC105376253 | LOC105376270 | LOC105376287 | LOC105376326 | LOC105376344 | LOC105376356 | LOC105376360 | LOC105376361 | LOC105376372 | LOC105376375 | LOC105376387 | LOC105376391 | LOC105376397 | LOC105376400 | LOC105376407 | LOC105376412 | LOC105376413 | LOC105376422 | LOC105376435 | LOC105376440 | LOC105376442 | LOC105376481 | LOC105376482 | LOC105376483 | LOC105376486 | LOC105376502 | LOC105376504 | LOC105376505 | LOC105376512 | LOC105376523 | LOC105376536 | LOC105376548 | LOC105376558 | LOC105376559 | LOC105376566 | LOC105376576 | LOC105376579 | LOC105376583 | LOC105376595 | LOC105376611 | LOC105376622 | LOC105376626 | LOC105376627 | LOC105376645 | LOC105376659 | LOC105376707 | LOC105376732 | LOC105376740 | LOC105376755 | LOC105376767 | LOC105376781 | LOC105376786 | LOC105376805 | LOC105376809 | LOC105376815 | LOC105376817 | LOC105376818 | LOC105376819 | LOC105376823 | LOC105376845 | LOC105376850 | LOC105376885 | LOC105376898 | LOC105376934 | LOC105376981 | LOC105376991 | LOC105377013 | LOC105377016 | LOC105377022 | LOC105377043 | LOC105377046 | LOC105377054 | LOC105377056 | LOC105377095 | LOC105377097 | LOC105377102 | LOC105377103 | LOC105377134 | LOC105377135 | LOC105377136 | LOC105377139 | LOC105377142
